BILIVIST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bilivist, and when can generic versions of Bilivist launch?
Bilivist is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in BILIVIST is ipodate sodium. There is one drug master file entry for this compound. Additional details are available on the ipodate sodium profile page.
Summary for BILIVIST
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 29 |
Patent Applications: | 260 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BILIVIST at DailyMed |
US Patents and Regulatory Information for BILIVIST
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | BILIVIST | ipodate sodium | CAPSULE;ORAL | 087768-001 | Aug 11, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |